Oligosecretory Waldenstrom macroglobulinemia exhibits excellent treatment response and outcomes

Wenjie Xiong,[1,2*] Ying Yu,[1,2*] Chunyan Sun,[3*] Juan Du,[4*] Zhen Cai,[5*] Zanzan Wang,[6] Xinxin Cao,[7] Yuting Yan,[1,2] Jiawen Chen,[1,2] Yanshan Huang,[1,2] Zhongxing Jiang,[8] Huihan Wang,[9] Ting Niu,[10] Guangzhong Yang,[11] Hua Xue,[12] Bingzong Li,[13] Honghui Huang,[14] Zhenling Li,[15] Qinhua Liu,[16] Fei Li,[17] Ou Bai,[18] Min Mao,[19] Rong Fu,[20] Ling Wang,[21] Chunrui Li,[3] Xiaoxia Chu,[22] Lihong Liu,[23] Yujun Dong,[24] Luqun Wang,[25] Jun Luo,[26] Yongqiang Wei,[27] Rui Cui,[28] Lugui Qiu,[1,2] Jian Li[7] and Shuhua Yi;[1,2] on behalf of the Chinese Workshop on Waldenström Macroglobulinemia (CWWM)

[1]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology Blood Diseases Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Tianjin; [2]Tianjin Institutes of Health Science, Tianjin; [3]Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei; [4]Department of Hematology, The Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai; [5]Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou; [6]Department of Hematology, Ningbo First Hospital, Zhejiang; [7]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing; [8]The First Affiliated Hospital of Zhengzhou University, Henan; [9]Shengjing Hospital of China Medical University, Liaoning; [10]West China Hospital Sichuan University, Chengdu, Sichuan; [11]Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing; [12]Affiliated Hospital of Hebei University, Hebei; [13]Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu; [14]Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai; [15]Department of Hematology, China-Japan Friendship Hospital, Beijing; [16]Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui; [17]The First Affiliated Hospital of Nanchang University, Jiangxi; [18]Department of Hematology, The First Hospital of Jilin University, Jilin; [19]Department of Hematology, Xinjiang Uiger Municipal People's Hospital, Xinjiang; [20]Department of Hematology, Tianjin Medical University General Hospital, Tianjin; [21]Qingdao Central Hospital, Shandong; [22]The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong; [23]Department of Hematology, The Fourth Hospital of Hebei Medical University, Hebei; [24]Department of Hematology, Peking University First Hospital, Beijing; [25]Department of Hematology, Qilu Hospital of Shandong University, Shandong; [26]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi; [27]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangdong and [28]Department of Hematology, Tianjin First Center Hospital, Tianjin, China

**WX, YYu, CS, JD and Zc contributed equally as first authors.*

Correspondence:
S. YI - yishuhua@ihcams.ac.cn
J. LI - lijian@pumch.cn

https://doi.org/10.3324/haematol.2023.283402

Received: April 27, 2023.
Accepted: September 1, 2023.
Early view: September 14, 2023.

Supplementary Table 1 Treatment regimens of newly diagnosed WM with measurable disease and oligosecretory WM

Regimens	Oligosecretory WM (N=45)	Measurable WM (N=682)	P
New drug regimens—no. (%)	29 (64.4)	409 (60.0)	0.568
R-based, n (%)	22 (48.9)	252 (37.0)	0.109
B-based, n (%)	3 (6.7)	111 (16.3)	0.086
BTK inhibitor, n (%)	4 (8.9)	46 (6.7)	0.582
Cytotoxic drug, n (%)	16 (35.6)	273 (40.0)	0.568

R, rituximab; B, bortezomib

Supplemental Figures:

Supplemental Figure 1: Kaplan-Meier curves for PFS and OS of oligosecretory WM patients according to IPSSWM. (A) The PFS of oligosecretory WM patients, (B) The OS of oligosecretory WM patients.

Supplemental Figure 2: Kaplan-Meier curves for PFS of oligosecretory WM patients with IgM levels higher than 10 g/L and lower than or equal to 10 g/L.

Supplemental Figure 1



Supplemental Figure 2